StockData
Citius Pharmaceuticals, Inc. logo

Citius Pharmaceuticals, Inc. (CTXR) stock

CTXRNasdaqPharmaceutical PreparationsFiscal year ends September 30
Financials through Q3 FY2026, quarter ended Jun 30, 2026Last filing: 10-Q on Aug 14, 2026Score 1/30
$0.53−0.01 (-1.40%)

Close on Nov 16, 2026Market cap $14.48MP/E –Yield –

Citius Pharmaceuticals r&d expenses

Research and development expenses are spending on new products and technology.

Citius Pharmaceuticals's R&D Expenses for the twelve months ending Jun 30, 2026 was $5.93M, down 43.2% year over year. For fiscal 2025 it was $9.16M, down 23.1% from the year before. The highest annual figure on record is $17.66M in fiscal 2022.

Annual r&d expenses

PeriodPeriod endValueChange
FY2025Sep 30, 2025$9.16M-23.1%
FY2024Sep 30, 2024$11.91M-19.7%
FY2023Sep 30, 2023$14.82M-16.1%
FY2022Sep 30, 2022$17.66M+44.2%
FY2021Sep 30, 2021$12.24M+38.9%
FY2020Sep 30, 2020$8.81M+6950.2%
FY2019Sep 30, 2019$125.00K-98.1%
FY2018Sep 30, 2018$6.56M+123.5%
FY2017Sep 30, 2017$2.94M+0.1%
FY2016Sep 30, 2016$2.93M–

Quarterly r&d expenses

Change is against the same quarter a year earlier.

Periods
PeriodPeriod endValueChange
Q3 FY2026CQ2 2026Jun 30, 2026$1.05M-35.0%
Q2 FY2026CQ1 2026Mar 31, 2026$1.63M-56.6%
Q1 FY2026CQ4 2025Dec 31, 2025$1.60M-24.8%
Q4 FY2025CQ3 2025Sep 30, 2025$1.64M-43.7%
Q3 FY2025CQ2 2025Jun 30, 2025$1.62M-41.3%
Q2 FY2025CQ1 2025Mar 31, 2025$3.77M+4.5%
Q1 FY2025CQ4 2024Dec 31, 2024$2.13M-18.9%
Q4 FY2024CQ3 2024Sep 30, 2024$2.91M+1.1%
Q3 FY2024CQ2 2024Jun 30, 2024$2.76M-19.8%
Q2 FY2024CQ1 2024Mar 31, 2024$3.61M-6.5%
Q1 FY2024CQ4 2023Dec 31, 2023$2.62M-46.4%
Q4 FY2023CQ3 2023Sep 30, 2023$2.88M-16.5%
Q1 FY2023CQ4 2022Dec 31, 2022$3.45M-36.9%
Q4 FY2022CQ3 2022Sep 30, 2022$3.86M+68.1%
Q3 FY2022CQ2 2022Jun 30, 2022$4.89M+121.8%
Q2 FY2022CQ1 2022Mar 31, 2022$3.45M+122.5%
Q1 FY2022CQ4 2021Dec 31, 2021$5.46M-11.8%
Q4 FY2021CQ3 2021Sep 30, 2021$2.29M+54.2%
Q3 FY2021CQ2 2021Jun 30, 2021$2.20M-16.7%
Q2 FY2021CQ1 2021Mar 31, 2021$1.55M-23.0%
Q1 FY2021CQ4 2020Dec 31, 2020$6.19M+132.4%
Q4 FY2020CQ3 2020Sep 30, 2020$1.49M-26.2%
Q3 FY2020CQ2 2020Jun 30, 2020$2.64M-4.4%
Q2 FY2020CQ1 2020Mar 31, 2020$2.02M+18.6%
Q1 FY2020CQ4 2019Dec 31, 2019$2.66M+26.1%
Q4 FY2019CQ3 2019Sep 30, 2019$2.02M+16.1%
Q3 FY2019CQ2 2019Jun 30, 2019$2.77M+255.2%
Q2 FY2019CQ1 2019Mar 31, 2019$1.70M-50.6%
Q1 FY2019CQ4 2018Dec 31, 2018$2.11M+248.4%
Q4 FY2018CQ3 2018Sep 30, 2018$1.74M+266.2%
Q3 FY2018CQ2 2018Jun 30, 2018$778.86K+308.5%
Q2 FY2018CQ1 2018Mar 31, 2018$3.44M+300.0%
Q1 FY2018CQ4 2017Dec 31, 2017$606.52K-57.0%
Q4 FY2017CQ3 2017Sep 30, 2017$474.53K-75.3%
Q3 FY2017CQ2 2017Jun 30, 2017$190.65K-50.0%
Q2 FY2017CQ1 2017Mar 31, 2017$859.92K–
Q1 FY2017CQ4 2016Dec 31, 2016$1.41M–
Q4 FY2016CQ3 2016Sep 30, 2016$1.92M–
Q3 FY2016CQ2 2016Jun 30, 2016$381.12K–

More Citius Pharmaceuticals figures

See a number that looks wrong?